Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren’s Syndrome

Bowman, S, Everett, CC orcid.org/0000-0002-9788-840X, O'Dwyer, JL orcid.org/0000-0002-7212-6089 et al. (20 more authors) (2017) Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren’s Syndrome. Arthritis & Rheumatology, 69 (7). pp. 1440-1450. ISSN 2326-5191

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2017, American College of Rheumatology. This is the peer reviewed version of the following article: Bowman, S. J., et al., (2017), Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's Syndrome. Arthritis & Rheumatology; which has been published in final form at https://doi.org/10.1002/art.40093. This article may be used for non-commercial purposes in accordance with the Wiley Terms and Conditions for Self-Archiving.
Dates:
  • Published: July 2017
  • Accepted: 8 March 2017
  • Published (online): 10 March 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 09 Mar 2017 11:19
Last Modified: 10 Mar 2018 01:38
Published Version: https://doi.org/10.1002/art.40093
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1002/art.40093

Share / Export

Statistics